ConductScience.org, home

Paper36765019

Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.

Jensen AB and 6 others. Obes Surg, 2023. Cited by 142 papers, by iCite.

Cite this record

ConductScience Library. Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study. Papers, record 36765019. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36765019

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.
PubMed
Journal
Obes Surg
PubMed
Year
2023
PubMed
Publication types
Observational Study, Journal Article
PubMed
Citations, by iCite
142
iCite
Relative citation ratio, by iCite
17.2
iCite
Revised in PubMed
2026-03-27
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Jensen ABAnders Boisenhttps://orcid.org/0000-0003-4752-041X
2Renström FFridahttps://orcid.org/0000-0001-6053-298X
3Aczél SStefan
4Folie PPatrick
5Biraima-Steinemann MMagdalena
6Beuschlein FFelix
7Bilz SStefan

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Bariatric SurgeryMajor topic
Diabetes Mellitus, Type 2Major topic
Obesity, MorbidMajor topic
Female
Humans
Male
Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Liraglutide
Weight Gain
Semaglutide

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT06132477Impact GLP-1 Agonists Following BariatricBackground

Source ClinicalTrials.gov

Download CSV of trials

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131677016Definitions of Long-Term Weight Regain and Their Associations with Clinical Outcomes.Obes Surg2020https://conductscience.org/library/papers/31677016PubMed
232870301Benefits and Risks of Bariatric Surgery in Adults: A Review.JAMA2020https://conductscience.org/library/papers/32870301PubMed
333392999Multidisciplinary Approach for Weight Regain-how to Manage this Challenging Condition: an Expert Review.Obes Surg2021https://conductscience.org/library/papers/33392999PubMed
430058859Current concepts in management of weight regain following bariatric surgery.Expert Rev Endocrinol Metab2018https://conductscience.org/library/papers/30058859PubMed
527295427Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.N Engl J Med2016https://conductscience.org/library/papers/27295427PubMed
627633186Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.N Engl J Med2016https://conductscience.org/library/papers/27633186PubMed
731422062Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.Lancet Diabetes Endocrinol2019https://conductscience.org/library/papers/31422062PubMed
818996762Synergistic weight loss and diabetes resolution with exenatide administration after laparoscopic gastric banding.Surg Obes Relat Dis2009https://conductscience.org/library/papers/18996762PubMed
927256860Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery.Surg Obes Relat Dis2016https://conductscience.org/library/papers/27256860PubMed
1030022424Efficacy of High-Dose Liraglutide as an Adjunct for Weight Loss in Patients with Prior Bariatric Surgery.Obes Surg2018https://conductscience.org/library/papers/30022424PubMed
1130768836Routine clinical use of liraglutide 3 mg for the treatment of obesity: Outcomes in non-surgical and bariatric surgery patients.Diabetes Obes Metab2019https://conductscience.org/library/papers/30768836PubMed
1231362076Liraglutide 3mg as a weight-loss strategy after failed bariatric surgery in a patient with hypothalamic obesity following craniopharyngioma.Diabetes Metab2020https://conductscience.org/library/papers/31362076PubMed
1334212346Initial Experience with Alternate-Day Liraglutide for Weight Regain Following Bariatric Surgery.Obes Surg2021https://conductscience.org/library/papers/34212346PubMed
1435060021Effectiveness and Safety of Liraglutide in Managing Inadequate Weight Loss and Weight Regain after Primary and Revisional Bariatric Surgery: Anthropometric and Cardiometabolic Outcomes.Obes Surg2022https://conductscience.org/library/papers/35060021PubMed
1531174993Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial.Lancet Diabetes Endocrinol2019https://conductscience.org/library/papers/31174993PubMed
1633492629Use of Weight Loss Medications in Patients after Bariatric Surgery.Curr Obes Rep2021https://conductscience.org/library/papers/33492629PubMed
1726132939A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.N Engl J Med2015https://conductscience.org/library/papers/26132939PubMed
1828110911
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Lancet Diabetes Endocrinol2017https://conductscience.org/library/papers/28110911PubMed
1933567185Once-Weekly Semaglutide in Adults with Overweight or Obesity.N Engl J Med2021https://conductscience.org/library/papers/33567185PubMed
2033652862Do Gut Hormones Contribute to Weight Loss and Glycaemic Outcomes after Bariatric Surgery?Nutrients2021https://conductscience.org/library/papers/33652862PubMed

See all 25 referencesDownload CSV of references

Cited by94

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 142 citations.

PMIDTitleJournalYearIn PapersSource
42720874Adipose Tissue Remodeling Beyond Weight Loss: New Insights Into Incretin-Based Therapies and Bariatric Surgery.Curr Obes Rep2026https://conductscience.org/library/papers/42720874PubMed
42718598Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42718598PubMed
42716982Anesthetic Safety and Perioperative Outcomes in GLP-1 Receptor Agonist-Treated Patients Undergoing Lipoabdominoplasty.Aesthetic Plast Surg2026https://conductscience.org/library/papers/42716982PubMed
42666183Clinical efficacy of tirzepatide for weight regain and suboptimal glycemic control following laparoscopic sleeve gastrectomy: a case series of three patients with obesity-associated type 2 diabetes.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42666183PubMed
42661796Weight Recurrence After Bariatric Surgery: Incretin-Based Therapies and the Evolving Role of Revisional Surgery.Cureus2026https://conductscience.org/library/papers/42661796PubMed
42608458Normal dopamine uptake ratio on [18F]FDOPA pet-imaging in obesity.Int J Obes (Lond)2026https://conductscience.org/library/papers/42608458PubMed
42471527Optimal Timing of GLP-1 Receptor Agonist Initiation in Patients with Obesity Eligible for Metabolic Bariatric Surgery.Obes Surg2026https://conductscience.org/library/papers/42471527PubMed
42446801Optimal Timing for Initiating Liraglutide 3.0 mg in Patients With Persistent Obesity Six Months After Metabolic and Bariatric Surgery.Obes Surg2026https://conductscience.org/library/papers/42446801PubMed
42382138Weight loss and cardiovascular outcomes with incretin-based therapies after metabolic and bariatric surgery: a nationwide US cohort study.EClinicalMedicine2026https://conductscience.org/library/papers/42382138PubMed
42334596Adjunctive use of glucagon-like peptide-1 receptor agonists after bariatric surgery: updated systematic review and meta-analysis of randomized controlled trials.Acta Diabetol2026https://conductscience.org/library/papers/42334596PubMed
42274840Refining the Bariatric Journey: A Proposed Neoadjuvant and Adjuvant Framework for GLP-1 Receptor Agonists Inspired by Oncology.Curr Obes Rep2026https://conductscience.org/library/papers/42274840PubMed
42265997
2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
J Am Coll Cardiol2026https://conductscience.org/library/papers/42265997PubMed
42225949The impact of adjuvant anti-obesity medications on 10-year weight loss outcomes after sleeve gastrectomy.Int J Obes (Lond)2026https://conductscience.org/library/papers/42225949PubMed
42160228Initiation of GLP-1 Receptor Agonists Treatment after Bariatric Metabolic Surgery and Major Adverse Cardiac Events.Obes Facts2026https://conductscience.org/library/papers/42160228PubMed
42154211Ring-Augmented Versus Standard Roux-en-Y Gastric Bypass: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.Obes Surg2026https://conductscience.org/library/papers/42154211PubMed
42124784GLP-1 Receptor Agonist Combination Therapy Before and After Metabolic and Bariatric Surgery: A Review of Outcomes.J Metab Bariatr Surg2026https://conductscience.org/library/papers/42124784PubMed
42010688Mechanisms of weight recurrence after bariatric surgery.Nutr Metab (Lond)2026https://conductscience.org/library/papers/42010688PubMed
41977175Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance.Int J Mol Sci2026https://conductscience.org/library/papers/41977175PubMed
41824845GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials.Medicine (Baltimore)2026https://conductscience.org/library/papers/41824845PubMed
41821791Gaps in obesity management in the UAE and the role of bariatric endoscopy.Front Gastroenterol (Lausanne)2023https://conductscience.org/library/papers/41821791PubMed

See all 94 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GIP2695PubTator's text mininghttps://conductscience.org/library/genes/2695NCBI Gene
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740NCBI Gene
INS3630PubTator's text mininghttps://conductscience.org/library/genes/3630NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36765019

GET https://conductscience.org/api/papers/v1/36765019/references?page=2